A Phase 1/2 interventional study of CC-220 and Dexamethasone in Multiple Myeloma, sponsored by Celgene. Active, not recruiting at 162 sites in 11 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-20.
Sponsored by Celgene (part of Bristol-Myers Squibb) · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 27 studies testing iberdomide in Multiple Myeloma — 11 open to participants now, 24 under way, 3 of them phase 3. iberdomide · Multiple Myeloma.
Among the 27 studies testing iberdomide in Multiple Myeloma, this one is the 4th largest by enrollment, is the only one that started in 2016, is one of 8 in phase 1/2, reaches primary completion later than 1 of the 23 other live ones, and was the 1st registered.
3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.
Browse Multiple Myeloma studies →11 of the 27 studies testing iberdomide in Multiple Myeloma are open now, in 8 countries. Recruiting first, the newest first:
Alfred Chung, MD · Sites in United States
Ages 18+
Mayo Clinic · Sites in United States
Ages 18+
Canadian Myeloma Research Group · Sites in Canada
Ages 65+
National Cancer Institute (NCI) · Sites in United States
Ages 18+
Omar Nadeem, MD · Sites in United States
Ages 18+
By country, each count listing its studies:
iberdomide: first FDA approval 2026 (ZENBEXUS). What it is approved for, and how studies give it, is on its page →
Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
27 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 14 · Phase 2 18 · Phase 3 3
First in 2016; this study’s year is marked. 1 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 466 is above the median of 41 across 3,008 interventional studies indexed under Multiple Myeloma.
Median enrollment 75 across the 27 interventional studies. None of them has completed or been terminated yet.
This tab as a report to print or save as PDF → With an account.
5 of 27 have an industry lead sponsor. The 10 most frequent:
This study is registered under Celgene, one of the names counted as Bristol-Myers Squibb. Under that name alone:
Celgene is the lead sponsor of 428 studies on the registry; 12 are open to participants now.
Of its 104 completed or terminated interventional studies of FDA-regulated products, 30 (29%) have results posted.
149 studies in Multiple Myeloma by Bristol-Myers Squibb: 9 open now, 18 under way, 6 of them phase 3. Of 120 finished, 43 (36%) have results posted.
Among the 149 studies in Multiple Myeloma by Bristol-Myers Squibb, this one is the 14th largest by enrollment of the 108 interventional ones that give a count, is one of 13 that started in 2016, is one of 12 in phase 1/2, reaches primary completion later than 0 of the 17 other live ones, and was the 93rd registered.
Bristol-Myers Squibb’s Multiple Myeloma studies by the year they started, since 2001.
8 of the studies testing iberdomide in Multiple Myeloma that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05558319Phase 3PETHEMA FoundationNDMM Patients Candidates for ASCT Comparing Extended VRD Plus vs. Isa-VRD vs. Isa-V-Iberdomide | 2027-04 |
| NCT04975997Phase 3CelgeneOpen-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) | 2027-11-16 |
| NCT05560399Icahn School of Medicine at Mount SinaiA Study of Iberdomide (CC-220) in Combination With Elotuzumab and Dexamethasone for Relapsed/Refractory Multiple Myeloma | 2026-11 |
| NCT06465316National Cancer Institute (NCI)Testing Teclistamab (TECVAYLI) in Combination With Iberdomide for Relapsed or Refractory Multiple Myeloma | 2026-12-31 |
| NCT05354557Memorial Sloan Kettering Cancer CenterStudy of Iberdomide in People With Multiple Myeloma Who Have Had an Autologous Hematopoietic Stem Cell Transplant (AHCT) | 2027-04-26 |
Add all 8 to your calendar (.ics) → With an account.
Among the 27 studies testing iberdomide in Multiple Myeloma, from their registry updates:
Among Bristol-Myers Squibb’s 149 in Multiple Myeloma:
This tab as a report to print or save as PDF → With an account.
This is a multicenter, multi-country, open-label, Phase 1b/2a dose-escalation study consisting of two parts: dose escalation (Part 1) for CC-220 monotherapy, CC-220 in combination with DEX, CC-220 in combination with DEX and DARA, CC-220 in combination with DEX and BTZ and CC-220 in combination with DEX and CFZ; and the expansion of the RP2D (Part 2) for CC-220 in combination with DEX for Relapsed Refractory Multiple Myeloma and CC-220 in combination with DEX and BTZ for Newly Diagnosed Multiple Myeloma.
Subjects assigned to CC-220 monotherapy, who develop progressive disease (PD) will have the option to receive DEX in addition to CC-220 after consultation with the Medical Monitor. The dose of CC-220 will not be higher than the dose of CC-220 used in combination with dexamethasone in Cohort B that has been determined to be safe. Progressive disease must be confirmed in accordance with international myeloma working group (IMWG) criteria.
The starting dose of DEX will be 40 mg for subjects who are ≤75 years of age and 20 mg for subjects who are >75 years of age, given once weekly. This treatment will continue until PD, unacceptable toxicity or the subject withdraws consent.
For Cohorts A and B, the starting dose level of CC-220, dose level 1, is 0.3 mg. A dose level -1, of 0.15 mg, may also be evaluated if the starting dose level of 0.3 mg for 21 days of a 28-day cycle is not tolerated. For Cohorts E and F, the starting dose level of CC-220, dose level 1, is one dose level below the maximum dose for Cohort B that has been determined to be safe by the dose escalation committee (DEC) at the start of enrollment for both cohorts. For Cohort E in addition to CC-220 and DEX, daratumumab will be administered intravenously (IV) at a 16mg/kg dose. For Cohort F in addition to CC-220 and DEX, bortezomib will be administered subcutaneous (SC) at a 1.3mg/m2 dose.
All subjects with a minimal response (MR) or better who discontinue study treatment in Part 1 or Part 2 of the study for a reason other than PD or withdrawal of consent from the study will be followed for response assessment every 28 days (every 21 days for Cohort F) until PD.
The study will be conducted in compliance with the International Council for Harmonisation (ICH) of Technical Requirements for Registration of Pharmaceuticals for Human Use/Good Clinical Practice (GCP) and applicable regulatory requirements.
The initiation of Part 2 will begin when the RP2D is established in Part 1 in either Cohort A or Cohort B. Either cohort may begin once the RP2D is determined for each cohort independently during Part 1. All expansion decisions will be determined by the DEC after review of all safety, PK, biomarker and preliminary efficacy data, as applicable. During Part 2, the Independent Expert Reviewer will review safety data and any other data deemed relevant so that subject safety is ensured.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
1. All subjects in RRMM cohorts must have a documented diagnosis of Multiple Myeloma and have defined as:
Light chain Multiple Myeloma without measurable disease in the serum or urine: serum immunoglobulin free light chain ≥ 10 mg/dL (100 mg/L) and abnormal serum immunoglobulin kappa lambda free light chain ratio 2. All subjects in RRMM cohorts must have documented disease progression on or within 60 days from the last dose of their last myeloma therapy. Subjects who had CAR T therapy as their last myeloma therapy must have documented disease progression.
3. (ECOG) performance status score of 0, 1 or 2 3. Subject must have documented diagnosis with previously untreated symptomatic MM as defined by the criteria below (Rajkumar, 2016): MM diagnostic criteria;
- Clonal bone marrow plasma cells ≥ 10% or -proven bony or extramedullary plasmacytoma
- Any one or more of the following myeloma defining events:
One or more of the following myeloma-related organ dysfunction (at least one of the following);
One or more of the following biomarkers of :
AND have measurable disease, as assessed by central laboratory, defined by any of the following:
- Immunoglobulin (Ig)G myeloma: serum M-protein level ≥ 1.0 g/dL or urine M-protein level ≥ 200 mg/24 hours; or
- IgA, IgM, IgD, or IgE multiple myeloma: serum M-protein level ≥ 0.5 g/dL or urine M-protein level ≥ 200 mg/24 hours; or
- Light chain multiple myeloma without measurable disease in serum or urine: serum FLC ≥ 100 mg/L and abnormal kappa lambda (κ/λ) ratio 4. Subjects in Cohort J1 are not considered by the investigator as eligible for high-dose chemotherapy and stem cell transplantation due to:
- Age ≥65 years, OR
- In subjects \<65 years: presence of important comorbid condition(s) likely to have a negative impact on tolerability of high-dose chemotherapy with autologous stem cell transplantation.
5. Subjects in Cohort J2 are considered by the investigator as eligible for high-dose chemotherapy and autologous stem cell transplantation according to the institution's criteria based on age, medical history, cardiac and pulmonary status, overall health and condition, co-morbid condition(s), physical examination, and laboratory data.
Exclusion Criteria:
1. Subject has nonsecretory multiple myeloma 2. Subjects with Plasma Cell leukemia or amyloidosis 3. Any of the following laboratory abnormalities
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Oral CC-220 at dose specified by cohort dose level from Day 1-21 of each 28-day cycle
Drug: CC-220
* Oral CC-220 at dose specified by cohort dose level from Day 1-21 of each 28-day cycle. * For subjects ≤ 75 years old, oral DEX 40 mg on Days 1, 8, 15, and 22 of each 28-day cycle. For subjects \>75 years old, DEX will be administered at 20 mg on Days 1, 8,15, and 22 of each 28-day cycle. Subjects who surpass the age of 75 years while on treatment may be switched to the 20 mg QD dosage based on the investigator's best judgment.
Drug: CC-220 · Drug: Dexamethasone
* Oral CC-220 at Recommended Phase 2 dose (RP2D) from Day 1-21 of each 28-day cycle * Oral DEX 40 mg on Days 1, 8, 15, and 22 of each 28-day cycle. For subjects \>75 years old, DEX will be administered at 20 mg on Days 1, 8, 15, and 22 of each 28-day cycle.
Drug: CC-220 · Drug: Dexamethasone
* Oral CC-220 at dose specified by cohort dose level from Day 1-21 of each 28-day cycle. * Oral DEX for subjects ≤ 75 years old at 40 mg on Days 1, 8, 15, and 22 of each 28-day cycle. For subjects \>75 years old, oral DEX at 20 mg on Days 1, 8, 15, and 22 of each 28-day cycle. * Intravenous DARA at dose 16mg/kg on Days 1, 8, 15, and 22 at cycle 1-2, Days 1, 15 at cycle 3-6, and Day 1 at cycle ≥7 of each 28-day cycle. Once the MTD and/or RP2D is determined in Cohort E (CC-220Dd), subjects will be enrolled at this dose level using SC DARA. * Oral CC-220 at dose specified by cohort dose level from Day 1-21 of each 28-day cycle. * Oral DEX for subjects ≤ 75 years old at 40 mg on Days 1, 8, 15, and 22 of each 28-day cycle. For subjects \>75 years old, oral DEX at 20 mg on Days 1, 8, 15, and 22 of each 28-day cycle. * Subcutaneous DARA at dose 1800 mg over 3 to 5 minutes on Days 1, 8, 15, and 22 at cycle 1-2, Days 1, 15 at cycle 3-6, and Day 1 at cycle ≥7 of each 28-day cycle.
Drug: CC-220 · Drug: Dexamethasone · Drug: Daratumumab · Drug: Daratumumab - 16mg/kg · Drug: Daratumumab- 1800mg
* Oral CC-220 at dose specified by cohort dose level from Day 1-14 of each 21-day cycle. * Oral DEX for subjects ≤ 75 years old at 40 mg on Days 1, 8, and 15 of each 21-day cycle. For subjects \>75 years old, oral DEX at 20 mg on Days 1, 8, and 15 of each 21-day cycle. * Subcutaneous BTZ at dose 1.3 mg/m\^2 on Days 1, 4, 8 and 11 at cycle 1-8, and Days 1, 8 at cycle ≥9 of each 21-day cycle.
Drug: CC-220 · Drug: Dexamethasone · Drug: Bortezomib · Drug: Bortezomib (BTZ)
* Oral CC-220 at dose specified by cohort dose level from Day 1-21 of each 28-day cycle * Intravenous (IV) CFZ (Carfilzomib)administered at a starting dose of 20 mg/m2 on C1D1; and at a dose specified by cohort dose level thereafter on days 1, 8, 15 of each 28-day cycle * Oral DEX (Dexamethasone) on Days 1, 8, 15, and 22 of each 28-day cycle. For subjects ≤ 75 years old, the DEX dose will be 40 mg. For subjects \> 75 years old, the DEX dose will be 20 mg
Drug: CC-220 · Drug: Dexamethasone · Drug: Carfilzomib
* Oral CC-220 at dose specified by cohort dose level from Day 1-21 of each 28-day cycle * Intravenous (IV) CFZ administered at a starting dose of 20 mg/m2 on C1D1; and at a dose level specified by cohort dose level thereafter Days 1, 2, 8, 9, 15, 16 of each 28-day cycle * Oral DEX on Days 1, 2, 8, 9, 15, 16, 22, 23 of each 28-day cycle. The DEX dose will be 20 mg
Drug: CC-220 · Drug: Dexamethasone · Drug: Carfilzomib
* Oral CC-220 at Recommended Phase 2 dose (RP2D) from Day 1-21 of each 28-day cycle * Oral DEX 40 mg on Days 1, 8, 15, and 22 of each 28-day cycle. For subjects \>75 years old, oral DEX will be administered at 20 mg on Days 1, 8, 15, and 22 of each 28-day cycle.
Drug: CC-220 · Drug: Dexamethasone
* Oral CC-220 at Recommended Phase 2 Dose from Day 1-14 of each 21-day cycle (Cycle 1 to 8) and from Day 1-21 of each 28-day cycle (Cycle 9 and above). * Oral DEX at Cycles 1 to 8, 20 mg (≤ 75 years old) or 10 mg (\> 75 years old) on Days 1, 2, 4, 5, 8, 9, 11 and 12 of each 21-day cycle and Cycles ≥ 9, 40 mg (≤ 75 years old) or 20 mg (\> 75 years old) on Days 1, 8, 15, and 22 of each 28-day cycle. * Subcutaneous BTZ at dose 1.3 mg/m2 on Days 1, 4, 8 and 11 at Cycle 1-8 of each 21-day cycle.
Drug: CC-220 · Drug: Dexamethasone · Drug: Bortezomib · Drug: Bortezomib (BTZ)
* Oral CC-220 at Recommended Phase 2 Dose from Day 1-14 of each 21-day cycle. * Oral DEX at 20 mg/day (≤ 75 years old) or 10 mg/day (\> 75 years old) for Cycles 1 to 6 on Days 1, 2, 4, 5, 8, 9, 11 and 12 of a 21-day cycle. * Subcutaneous BTZ at dose 1.3 mg/m2 on Days 1, 4, 8 and 11 at Cycle 1-6 of each 21-day cycle.
Drug: CC-220 · Drug: Dexamethasone · Drug: Bortezomib · Drug: Bortezomib (BTZ)
Oral CC-220 at 1.0mg, 1.3mg or 1.6mg from Days 1-21 of each 28-day cycle. Oral DEX 40 mg on Days 1, 8, 15, and 22 of each 28-day cycle. For subjects \>75 years old, oral DEX will be administered at 20 mg on Days 1, 8, 15, and 22 of each 28-day cycle. Subcutaneous DARA at 1800 mg over 3 to 5minutes on Days 1, 8, 15, and 22 at cycle 1-2 of a 28-day cycle, Days1, and 15 at cycle 3-6 of a 28-day cycle, and Day1 at cycle ≥7 of each 28-day cycle.
Drug: Daratumumab
CC-220 at dose specified by cohort dose level from Day 1-21 of each 28-day cycle.
Also known as: Iberdomide
Oral DEX 40 mg on Days 1, 8, 15, and 22 of each 28-day cycle. For subjects \>75 years old, oral DEX will be administered at 20 mg on Days 1, 8, 15, and 22 of each 28-day cycle.
Also known as: Decadron
Specified dose on specified days
Also known as: Darzalex
Specified dose on specified days
Also known as: Velcade
Intravenous (IV) CFZ administered at a starting dose of 20 mg/m2 on C1D1 and C1D2; and at a dose level specified by cohort dose level thereafter Days 1, 2, 8, 9, 15, 16 of each 28-day cycle.
Also known as: Kyprolis
Drug page: Daratumumab
Daratumumab (DARA) 16mg/kg by intravenous infusion on Days 1, 8, 15, and 22 at cycle 1-2, Days 1, 15 at cycle 3-6, and Day 1 at cycle ≥7 of each 28-day cycle.
Also known as: Darzalex
Bortezomib 1.3 mg/m\^2 on Days 1, 4, 8 and 11 at cycle 1-8, and Days 1, 8 at cycle ≥9 of each 21-day cycle.
Also known as: Velcade
Daratumumab (DARA) 1800 mg by subcutaneous injection on Days 1, 8, 15, and 22 at cycle 1-2, Days 1, 15 at cycle 3-6, and Day 1 at cycle ≥7 of each 28-day cycle.
Also known as: Darzalex Faspro
Number of Participants With Dose Limiting Toxicities in Part 1.
The dose-limiting toxicity (DLT) population includes subjects who missed no more than 4 doses of CC-220, 2 doses of DEX, 1 dose of IV DARA (Cohort E), 1 dose of BTZ (Cohort F), or 1 dose of CFZ (Cohort G1 or G2) during Cycle 1 for reasons other than DLT. This population will be used for analyzing the primary endpoint regarding the determination of the MTD. Hematologic DLTs: Grade 4 neutropenia (ANC \<500/μL for \>5 days) Grade 3 neutropenia (ANC \<1,000/μL) with fever ≥38.5°C Grade 4 thrombocytopenia (platelet count \<25,000/μL) or Grade 3 thrombocytopenia with bleeding or need for platelet transfusion Any other grade 4 hematologic toxicity, except anemia, not resolving to pretreatment baseline within 72 hours. Non-hematologic DLT: Any non-hematological toxicity ≥ Grade 3, except alopecia and nausea controlled by medical management.
Time frame: From first dose to 28 days post last dose (up to 28 days)
Overall Response Rate (ORR) in Cohort D and Cohort H2
Tumor response, including progressive disease (PD) according to the IMWG Uniform Response Criteria (Kumar, 2016) for subjects who achieved partial response (PR) or better.
Time frame: Approximately on average (Cohort D: 21.14 weeks, Cohort H2: 22.11 Weeks)
Number of Participants With Treatment Related Adverse Events
An AE is any noxious, unintended, or untoward medical occurrence that may appear or worsen in a participant during the course of a study. It may be a new intercurrent illness, a worsening concomitant illness, an injury, or any concomitant impairment of the subject's health, including laboratory test values, regardless of etiology. Any worsening (ie, any clinically significant adverse change in the frequency or intensity of a preexisting condition) should be considered an AE.
Time frame: Approximately on average of (Cohort A: 16.23 Cohort B: 10.32 Cohort D: 18.68 Cohort E: 15.65 Cohort F: 12.66 Cohort G: 16.03 Cohort H1: 17.22 Cohort H2: 21.07 Cohort I: 17.10 Cohort J: 20.56 Cohort K: 13.56) Months
Number of Participants With Treatment Emergent Adverse Events of Special Interest (AESI)
An adverse event of special interest (AESI) is one of scientific and medical interest specific to understanding the safety profile of the Investigational Product, CC-220, and may require close monitoring and rapid communication by the Investigator to the Sponsor. An AESI may be serious or nonserious. The rapid reporting of AESIs allows ongoing surveillance of these events in order to characterize and understand their association with the use of this investigational product.
Time frame: Approximately on average of (Cohort A: 16.23 Cohort B: 10.32 Cohort D: 18.68 Cohort E: 15.65 Cohort F: 12.66 Cohort G: 16.03 Cohort H1: 17.22 Cohort H2: 21.07 Cohort I: 17.10 Cohort J: 20.56 Cohort K: 13.56) Months
Very Good Partial Response Rate (ORR) in Cohort J1 and Cohort K
The very good partial response or better (≥ VGPR) rate is defined as the proportion of subjects with best response of VGPR or better during the trial without administration of myeloma therapy other than study treatment. The ≥ VGPR rate with 95% confidence interval (CI) together with the proportions in each response category based on the IMWG Uniform Response Criteria.
Time frame: On Average of (Cohort J: 86.21, Cohort K: 56.29) Weeks
Overall Response Rate (ORR)
Tumor response, including progressive disease (PD) according to the IMWG Uniform Response Criteria (Kumar, 2016) for subjects who achieved partial response (PR) or better.
Time frame: On Average of (Cohort A: 44.96, Cohort B: 32.79, Cohort D: 21.14, Cohort E: 53.74, Cohort F: 46.34, Cohort G: 63.26, Cohort H1: 58.10, Cohort H2: 22.11, Cohort I: 20.96, Cohort J: 86.21, Cohort K: 56.29) Weeks
Time to Response (TTR)
Time to response is defined as the time from the first dose date of study treatment to the first date of documented response (PR or better). Time to response will be summarized for responders using descriptive statistics by cohort and dose level.
Time frame: On Average of (Cohort A:19.14, Cohort B: 12.39, Cohort D: 7.54, Cohort E: 5.44, Cohort F: 4.97, Cohort G: 12.30, Cohort H: 4.14, Cohort I: 8.79, Cohort J: 4.76, Cohort K: 6.51) Weeks
Duration of Response
Duration of response is defined as time from the earliest date of documented response (PR or better) to the earliest date of disease progression per IMWG Uniform Response Criteria or death, whichever occurred first. Participants who do not have progression of disease or death will be censored on the last adequate response assessment date. Duration of response for responders will be summarized using Kaplan-Meier estimates by cohort and dose level as appropriate. Data will be collected and analyzed per Cohort Totals.
Time frame: On Average of (Cohort A:161.33, Cohort B: 63.74, Cohort D: 39.16, Cohort E: 89.56, Cohort F: 69.24, Cohort G: 80.93, Cohort H1: 77.11, Cohort H2: 42.71, Cohort I: 36.80, Cohort J: 92.36, Cohort K: 51.85) Weeks
Progression Free Survival
Time from the first dose of investigational product (IP) to the first documentation of PD or death from any cause, whichever occurs first Data will be collected and analyzed per Cohort Totals.
Time frame: On Average of (Cohort A: 44.96, Cohort B: 32.79, Cohort D: 21.14, Cohort E: 53.74, Cohort F: 46.34, Cohort G: 63.26, Cohort H1: 58.10, Cohort H2: 22.11, Cohort I: 20.96, Cohort J: 86.21, Cohort K: 56.29) Weeks
Overall Survival for Cohort D, Cohort H2 and Cohort I
Time from first dose of IP to death due to any cause Data will be collected and analyzed per Cohort Totals.
Time frame: On Average of (Cohort D: 81.14 Cohort H2: 91.54 Cohort I: 74.20)Weeks
Auc(Tau)
Area under the plasma concentration time-curve. AUC over the dosing interval.
Time frame: From Cycle 1 Day 1 to Cycle 1 Day 15 (15 days)
Cmax
Cmax is defined as maximum plasma concentration of the drug.
Time frame: From Cycle 1 Day 1 to Cycle 1 Day 15 (15 days)
Tmax
Tmax is defined is the time to maximum plasma concentration.
Time frame: From Cycle 1 Day 1 to Cycle 1 Day 15 (15 days)
| Milestone | Cohort A: Treatment 1 | Cohort A: Treatment 2 | Cohort A: Treatment 3 | Cohort A: Treatment 4 | Cohort A: Treatment 5 | Cohort A: Treatment 6 | Cohort B: Treatment 1 | Cohort B: Treatment 2 | Cohort B: Treatment 3 | Cohort B: Treatment 4 | Cohort B: Treatment 5 | Cohort B: Treatment 6 | Cohort B: Treatment 7 | Cohort B: Treatment 8 | Cohort B: Treatment 9 | Cohort B: Treatment 10 | Cohort D: Treatment 1 | Cohort E: Treatment 1 | Cohort E: Treatment 2 | Cohort E: Treatment 3 | Cohort E: Treatment 4 | Cohort E: Treatment 5 | Cohort F: Treatment 1 | Cohort F: Treatment 2 | Cohort F: Treatment 3 | Cohort F: Treatment 4 | Cohort G: Treatment 1 | Cohort G: Treatment 2 | Cohort G: Treatment 3 | Cohort H1 | Cohort H2 | Cohort I | Cohort J1: Treatment 1 | Cohort J1: Treatment 2 | Cohort K: Treatment 1 | Cohort K: Treatment 2 | Cohort K: Treatment 3 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 3 | 3 | 4 | 6 | 6 | 7 | 10 | 3 | 3 | 3 | 13 | 13 | 10 | 8 | 14 | 13 | 107 | 3 | 3 | 5 | 13 | 26 | 3 | 7 | 10 | 9 | 4 | 8 | 4 | 6 | 5 | 41 | 1 | 17 | 25 | 25 | 25 |
| Completed | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 1 | 4 | 0 | 1 | 0 | 0 | 1 | 1 | 2 | 1 | 0 | 0 | 1 | 10 | 22 | 20 | 20 |
| Not completed | 2 | 3 | 4 | 6 | 6 | 7 | 10 | 3 | 3 | 3 | 13 | 13 | 10 | 8 | 14 | 12 | 107 | 3 | 3 | 4 | 12 | 22 | 3 | 6 | 10 | 9 | 3 | 7 | 2 | 5 | 5 | 41 | 0 | 7 | 3 | 5 | 5 |
| Milestone | Cohort A: Treatment 1 | Cohort A: Treatment 2 | Cohort A: Treatment 3 | Cohort A: Treatment 4 | Cohort A: Treatment 5 | Cohort A: Treatment 6 | Cohort B: Treatment 1 | Cohort B: Treatment 2 | Cohort B: Treatment 3 | Cohort B: Treatment 4 | Cohort B: Treatment 5 | Cohort B: Treatment 6 | Cohort B: Treatment 7 | Cohort B: Treatment 8 | Cohort B: Treatment 9 | Cohort B: Treatment 10 | Cohort D: Treatment 1 | Cohort E: Treatment 1 | Cohort E: Treatment 2 | Cohort E: Treatment 3 | Cohort E: Treatment 4 | Cohort E: Treatment 5 | Cohort F: Treatment 1 | Cohort F: Treatment 2 | Cohort F: Treatment 3 | Cohort F: Treatment 4 | Cohort G: Treatment 1 | Cohort G: Treatment 2 | Cohort G: Treatment 3 | Cohort H1 | Cohort H2 | Cohort I | Cohort J1: Treatment 1 | Cohort J1: Treatment 2 | Cohort K: Treatment 1 | Cohort K: Treatment 2 | Cohort K: Treatment 3 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 3 | 3 | 4 | 6 | 6 | 7 | 10 | 3 | 3 | 3 | 13 | 13 | 10 | 8 | 14 | 13 | 107 | 3 | 3 | 5 | 13 | 26 | 3 | 7 | 10 | 9 | 4 | 8 | 4 | 6 | 5 | 41 | 1 | 17 | 25 | 25 | 25 |
| Completed | 2 | 2 | 3 | 4 | 5 | 6 | 9 | 3 | 2 | 3 | 11 | 10 | 10 | 6 | 7 | 8 | 2 | 3 | 2 | 4 | 11 | 15 | 1 | 5 | 8 | 4 | 3 | 4 | 1 | 5 | 0 | 4 | 0 | 1 | 0 | 1 | 0 |
| Not completed | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 0 | 1 | 0 | 2 | 3 | 0 | 2 | 7 | 5 | 105 | 0 | 1 | 1 | 2 | 11 | 2 | 2 | 2 | 5 | 1 | 4 | 3 | 1 | 5 | 37 | 1 | 16 | 25 | 24 | 25 |
| Withdrew: Death | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 2 | 0 | 1 | 2 | 2 | 78 | 0 | 0 | 0 | 0 | 3 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 3 | 24 | 0 | 1 | 1 | 2 | 2 |
| Withdrew: Progressive disease | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 0 | 2 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 2 | 1 | 5 | 0 | 1 | 0 | 1 | 4 | 2 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 3 | 0 | 2 | 0 | 1 | 1 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Other reasons | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 1 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 |
| Withdrew: Still on-going | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 20 | 0 | 0 | 1 | 1 | 4 | 0 | 1 | 0 | 0 | 1 | 1 | 2 | 1 | 2 | 9 | 1 | 12 | 22 | 21 | 22 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Physician decision | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
The dose-limiting toxicity (DLT) population includes subjects who missed no more than 4 doses of CC-220, 2 doses of DEX, 1 dose of IV DARA (Cohort E), 1 dose of BTZ (Cohort F), or 1 dose of CFZ (Cohort G1 or G2) during Cycle 1 for reasons other than DLT. This population will be used for analyzing the primary endpoint regarding the determination of the MTD. Hematologic DLTs: Grade 4 neutropenia (ANC \<500/μL for \>5 days) Grade 3 neutropenia (ANC \<1,000/μL) with fever ≥38.5°C Grade 4 thrombocytopenia (platelet count \<25,000/μL) or Grade 3 thrombocytopenia with bleeding or need for platelet transfusion Any other grade 4 hematologic toxicity, except anemia, not resolving to pretreatment baseline within 72 hours. Non-hematologic DLT: Any non-hematological toxicity ≥ Grade 3, except alopecia and nausea controlled by medical management.
| Participants | Cohort A: Treatment 1 | Cohort A: Treatment 2 | Cohort A: Treatment 3 | Cohort A: Treatment 4 | Cohort A: Treatment 5 | Cohort A: Treatment 6 | Cohort B: Treatment 1 | Cohort B: Treatment 2 | Cohort B: Treatment 3 | Cohort B: Treatment 4 | Cohort B: Treatment 5 | Cohort B: Treatment 6 | Cohort B: Treatment 7 | Cohort B: Treatment 8 | Cohort B: Treatment 9 | Cohort B: Treatment 10 | Cohort D: Treatment 1 | Cohort E: Treatment 1 | Cohort E: Treatment 2 | Cohort E: Treatment 3 | Cohort E: Treatment 4 | Cohort E: Treatment 5 | Cohort F: Treatment 1 | Cohort F: Treatment 2 | Cohort F: Treatment 3 | Cohort F: Treatment 4 | Cohort G: Treatment 1 | Cohort G: Treatment 2 | Cohort G: Treatment 3 | Cohort H1 | Cohort H2 | Cohort I | Cohort J1: Treatment 1 | Cohort J1: Treatment 2 | Cohort K: Treatment 1 | Cohort K: Treatment 2 | Cohort K: Treatment 3 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Number of Participants With Dose Limiting Toxicities in Part 1. | 0 | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | — | — | — | — | — | — | 0 | 1 | 0 | 1 | 0 | 1 | 1 | 1 | — | — | — | — | — | — | — |
Tumor response, including progressive disease (PD) according to the IMWG Uniform Response Criteria (Kumar, 2016) for subjects who achieved partial response (PR) or better.
| Percentage of Participants | Cohort A: Treatment 1 | Cohort A: Treatment 2 | Cohort A: Treatment 3 | Cohort A: Treatment 4 | Cohort A: Treatment 5 | Cohort A: Treatment 6 | Cohort B: Treatment 1 | Cohort B: Treatment 2 | Cohort B: Treatment 3 | Cohort B: Treatment 4 | Cohort B: Treatment 5 | Cohort B: Treatment 6 | Cohort B: Treatment 7 | Cohort B: Treatment 8 | Cohort B: Treatment 9 | Cohort B: Treatment 10 | Cohort D: Treatment 1 | Cohort E: Treatment 1 | Cohort E: Treatment 2 | Cohort E: Treatment 3 | Cohort E: Treatment 4 | Cohort E: Treatment 5 | Cohort F: Treatment 1 | Cohort F: Treatment 2 | Cohort F: Treatment 3 | Cohort F: Treatment 4 | Cohort G: Treatment 1 | Cohort G: Treatment 2 | Cohort G: Treatment 3 | Cohort H1 | Cohort H2 | Cohort I | Cohort J1: Treatment 1 | Cohort J1: Treatment 2 | Cohort K: Treatment 1 | Cohort K: Treatment 2 | Cohort K: Treatment 3 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Response Rate (ORR) in Cohort D and Cohort H2 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 26.2 (18.1 to 35.6) | — | — | — | — | — | — | — | — | — | — | — | — | — | 20.0 (0.5 to 71.6) | — | — | — | — | — | — |
An AE is any noxious, unintended, or untoward medical occurrence that may appear or worsen in a participant during the course of a study. It may be a new intercurrent illness, a worsening concomitant illness, an injury, or any concomitant impairment of the subject's health, including laboratory test values, regardless of etiology. Any worsening (ie, any clinically significant adverse change in the frequency or intensity of a preexisting condition) should be considered an AE.
| Participants | Cohort A: Treatment 1 | Cohort A: Treatment 2 | Cohort A: Treatment 3 | Cohort A: Treatment 4 | Cohort A: Treatment 5 | Cohort A: Treatment 6 | Cohort B: Treatment 1 | Cohort B: Treatment 2 | Cohort B: Treatment 3 | Cohort B: Treatment 4 | Cohort B: Treatment 5 | Cohort B: Treatment 6 | Cohort B: Treatment 7 | Cohort B: Treatment 8 | Cohort B: Treatment 9 | Cohort B: Treatment 10 | Cohort D: Treatment 1 | Cohort E: Treatment 1 | Cohort E: Treatment 2 | Cohort E: Treatment 3 | Cohort E: Treatment 4 | Cohort E: Treatment 5 | Cohort F: Treatment 1 | Cohort F: Treatment 2 | Cohort F: Treatment 3 | Cohort F: Treatment 4 | Cohort G: Treatment 1 | Cohort G: Treatment 2 | Cohort G: Treatment 3 | Cohort H1 | Cohort H2 | Cohort I | Cohort J1: Treatment 1 | Cohort J1: Treatment 2 | Cohort K: Treatment 1 | Cohort K: Treatment 2 | Cohort K: Treatment 3 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Number of Participants With Treatment Related Adverse Events | 2 | 3 | 3 | 6 | 6 | 7 | 8 | 3 | 2 | 3 | 9 | 10 | 8 | 7 | 13 | 11 | 95 | 0 | 3 | 5 | 12 | 23 | 3 | 7 | 7 | 8 | 4 | 6 | 4 | 6 | 5 | 30 | 1 | 15 | 24 | 24 | 23 |
An adverse event of special interest (AESI) is one of scientific and medical interest specific to understanding the safety profile of the Investigational Product, CC-220, and may require close monitoring and rapid communication by the Investigator to the Sponsor. An AESI may be serious or nonserious. The rapid reporting of AESIs allows ongoing surveillance of these events in order to characterize and understand their association with the use of this investigational product.
| Participants | Cohort A: Treatment 1 | Cohort A: Treatment 2 | Cohort A: Treatment 3 | Cohort A: Treatment 4 | Cohort A: Treatment 5 | Cohort A: Treatment 6 | Cohort B: Treatment 1 | Cohort B: Treatment 2 | Cohort B: Treatment 3 | Cohort B: Treatment 4 | Cohort B: Treatment 5 | Cohort B: Treatment 6 | Cohort B: Treatment 7 | Cohort B: Treatment 8 | Cohort B: Treatment 9 | Cohort B: Treatment 10 | Cohort D: Treatment 1 | Cohort E: Treatment 1 | Cohort E: Treatment 2 | Cohort E: Treatment 3 | Cohort E: Treatment 4 | Cohort E: Treatment 5 | Cohort F: Treatment 1 | Cohort F: Treatment 2 | Cohort F: Treatment 3 | Cohort F: Treatment 4 | Cohort G: Treatment 1 | Cohort G: Treatment 2 | Cohort G: Treatment 3 | Cohort H1 | Cohort H2 | Cohort I | Cohort J1: Treatment 1 | Cohort J1: Treatment 2 | Cohort K: Treatment 1 | Cohort K: Treatment 2 | Cohort K: Treatment 3 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Number of Participants With Treatment Emergent Adverse Events of Special Interest (AESI) | 1 | 0 | 0 | 1 | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 9 | 0 | 0 | 0 | 1 | 2 | 0 | 0 | 1 | 3 | 1 | 0 | 1 | — | — | — | 0 | 4 | 2 | 0 | 0 |
The very good partial response or better (≥ VGPR) rate is defined as the proportion of subjects with best response of VGPR or better during the trial without administration of myeloma therapy other than study treatment. The ≥ VGPR rate with 95% confidence interval (CI) together with the proportions in each response category based on the IMWG Uniform Response Criteria.
| Percentage of Participants | Cohort A: Treatment 1 | Cohort A: Treatment 2 | Cohort A: Treatment 3 | Cohort A: Treatment 4 | Cohort A: Treatment 5 | Cohort A: Treatment 6 | Cohort B: Treatment 1 | Cohort B: Treatment 2 | Cohort B: Treatment 3 | Cohort B: Treatment 4 | Cohort B: Treatment 5 | Cohort B: Treatment 6 | Cohort B: Treatment 7 | Cohort B: Treatment 8 | Cohort B: Treatment 9 | Cohort B: Treatment 10 | Cohort D: Treatment 1 | Cohort E: Treatment 1 | Cohort E: Treatment 2 | Cohort E: Treatment 3 | Cohort E: Treatment 4 | Cohort E: Treatment 5 | Cohort F: Treatment 1 | Cohort F: Treatment 2 | Cohort F: Treatment 3 | Cohort F: Treatment 4 | Cohort G: Treatment 1 | Cohort G: Treatment 2 | Cohort G: Treatment 3 | Cohort H1 | Cohort H2 | Cohort I | Cohort J1: Treatment 1 | Cohort J1: Treatment 2 | Cohort K: Treatment 1 | Cohort K: Treatment 2 | Cohort K: Treatment 3 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Very Good Partial Response Rate (ORR) in Cohort J1 and Cohort K | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 100.0 (2.5 to 100.0) | 82.4 (56.6 to 96.2) | 72.0 (50.6 to 87.9) | 100.00 (86.3 to 100.0) | 88.0 (68.8 to 97.5) |
Tumor response, including progressive disease (PD) according to the IMWG Uniform Response Criteria (Kumar, 2016) for subjects who achieved partial response (PR) or better.
| Percentage of Participants | Cohort A: Treatment 1 | Cohort A: Treatment 2 | Cohort A: Treatment 3 | Cohort A: Treatment 4 | Cohort A: Treatment 5 | Cohort A: Treatment 6 | Cohort B: Treatment 1 | Cohort B: Treatment 2 | Cohort B: Treatment 3 | Cohort B: Treatment 4 | Cohort B: Treatment 5 | Cohort B: Treatment 6 | Cohort B: Treatment 7 | Cohort B: Treatment 8 | Cohort B: Treatment 9 | Cohort B: Treatment 10 | Cohort D: Treatment 1 | Cohort E: Treatment 1 | Cohort E: Treatment 2 | Cohort E: Treatment 3 | Cohort E: Treatment 4 | Cohort E: Treatment 5 | Cohort F: Treatment 1 | Cohort F: Treatment 2 | Cohort F: Treatment 3 | Cohort F: Treatment 4 | Cohort G: Treatment 1 | Cohort G: Treatment 2 | Cohort G: Treatment 3 | Cohort H1 | Cohort H2 | Cohort I | Cohort J1: Treatment 1 | Cohort J1: Treatment 2 | Cohort K: Treatment 1 | Cohort K: Treatment 2 | Cohort K: Treatment 3 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Response Rate (ORR) | 0 (0.0 to 70.8) | 0 (0.0 to 70.8) | 0 (0.0 to 60.2) | 33.3 (4.3 to 77.7) | 0 (0.0 to 45.9) | 14.3 (0.4 to 57.9) | 30.0 (6.7 to 65.2) | 33.3 (0.8 to 90.6) | 33.3 (0.8 to 90.6) | 66.7 (9.4 to 99.2) | 30.8 (9.1 to 61.4) | 23.1 (5.0 to 53.8) | 20.0 (2.5 to 55.6) | 25.0 (3.2 to 65.1) | 50.0 (23.0 to 77.0) | 30.8 (9.1 to 61.4) | 26.2 (18.1 to 35.6) | 0 (0.0 to 70.8) | 33.3 (0.8 to 90.6) | 20.0 (0.5 to 71.6) | 61.5 (31.6 to 86.1) | 53.8 (33.4 to 73.4) | 33.3 (0.8 to 90.6) | 42.9 (9.9 to 81.6) | 70.0 (34.8 to 93.3) | 66.7 (29.9 to 92.5) | 75.0 (19.4 to 99.4) | 50.0 (15.7 to 84.3) | 75.0 (19.4 to 99.4) | 66.7 (22.3 to 95.7) | 20.0 (0.5 to 71.6) | 34.1 (20.1 to 50.6) | 100.0 (2.5 to 100.0) | 82.4 (56.6 to 96.2) | 96.0 (79.6 to 99.9) | 100.0 (86.3 to 100.0) | 88.0 (68.8 to 97.5) |
Time to response is defined as the time from the first dose date of study treatment to the first date of documented response (PR or better). Time to response will be summarized for responders using descriptive statistics by cohort and dose level.
| Weeks | Cohort A: Treatment 1 | Cohort A: Treatment 2 | Cohort A: Treatment 3 | Cohort A: Treatment 4 | Cohort A: Treatment 5 | Cohort A: Treatment 6 | Cohort B: Treatment 1 | Cohort B: Treatment 2 | Cohort B: Treatment 3 | Cohort B: Treatment 4 | Cohort B: Treatment 5 | Cohort B: Treatment 6 | Cohort B: Treatment 7 | Cohort B: Treatment 8 | Cohort B: Treatment 9 | Cohort B: Treatment 10 | Cohort D: Treatment 1 | Cohort E: Treatment 1 | Cohort E: Treatment 2 | Cohort E: Treatment 3 | Cohort E: Treatment 4 | Cohort E: Treatment 5 | Cohort F: Treatment 1 | Cohort F: Treatment 2 | Cohort F: Treatment 3 | Cohort F: Treatment 4 | Cohort G: Treatment 1 | Cohort G: Treatment 2 | Cohort G: Treatment 3 | Cohort H1 | Cohort H2 | Cohort I | Cohort J1: Treatment 1 | Cohort J1: Treatment 2 | Cohort K: Treatment 1 | Cohort K: Treatment 2 | Cohort K: Treatment 3 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Time to Response (TTR) | — | — | — | 24.64 (8.1 to 41.1) | — | 8.14 (8.14 to 8.14) | 7.86 (5.7 to 8.1) | 56.0 (56.0 to 56.0) | 8.14 (8.14 to 8.14) | 33.14 (10.1 to 56.1) | 4.14 (4.1 to 8.3) | 7.14 (4.1 to 16.1) | 12.14 (4.1 to 20.1) | 10.21 (8.4 to 12.0) | 8.14 (4.1 to 20.4) | 8.07 (4.3 to 12.1) | 4.21 (3.9 to 19.9) | — | 4.14 (4.14 to 4.14) | 7.86 (7.86 to 7.86) | 4.14 (4.1 to 12.0) | 4.14 (4.0 to 13.1) | 6.14 (6.14 to 6.14) | 3.14 (3.1 to 13.1) | 3.71 (3.1 to 9.1) | 3.36 (3.0 to 7.3) | 4.14 (4.1 to 8.1) | 8.14 (4.0 to 62.1) | 8.86 (4.1 to 11.1) | 6.14 (4.1 to 8.3) | 4.14 (4.14 to 4.14) | 6.29 (4.1 to 23.3) | 3.14 (3.14 to 3.14) | 3.14 (3.0 to 17.0) | 5.07 (4.0 to 49.0) | 4.14 (4.0 to 25.1) | 4.14 (4.0 to 9.3) |
Duration of response is defined as time from the earliest date of documented response (PR or better) to the earliest date of disease progression per IMWG Uniform Response Criteria or death, whichever occurred first. Participants who do not have progression of disease or death will be censored on the last adequate response assessment date. Duration of response for responders will be summarized using Kaplan-Meier estimates by cohort and dose level as appropriate. Data will be collected and analyzed per Cohort Totals.
| Weeks | Cohort A: Total | Cohort B: Total | Cohort D: Total | Cohort E: Total | Cohort F: Total | Cohort G: Total | Cohort H1 | Cohort H2 | Cohort I | Cohort J: Total | Cohort K |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Duration of Response | 176.14 (40.7 to 267.1) | 45.00 (7.4 to 239.3) | 28.64 (2.9 to 146.1) | 59.21 (9.1 to 265.1) | 69.29 (6.6 to 255.1) | 66.64 (22.7 to 238.3) | 43.57 (12.1 to 209.1) | 42.71 (42.71 to 42.71) | 32.79 (8.0 to 80.1) | 104.71 (17.0 to 123.1) | 52.14 (21.0 to 77.3) |
Time from the first dose of investigational product (IP) to the first documentation of PD or death from any cause, whichever occurs first Data will be collected and analyzed per Cohort Totals.
| Weeks | Cohort A: Total | Cohort B: Total | Cohort D: Total | Cohort E: Total | Cohort F: Total | Cohort G: Total | Cohort H1 | Cohort H2 | Cohort I | Cohort J: Total | Cohort K |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Progression Free Survival | 12.29 (0.1 to 395.0) | 14.71 (0.1 to 247.0) | 12.14 (0.1 to 150.1) | 20.71 (2.1 to 269.1) | 15.14 (0.1 to 258.1) | 48.57 (4.1 to 246.3) | 26.14 (5.3 to 213.1) | 22.14 (8.3 to 46.7) | 10.14 (0.1 to 84.4) | 107.00 (0.1 to 127.9) | 57.14 (0.1 to 81.3) |
Time from first dose of IP to death due to any cause Data will be collected and analyzed per Cohort Totals.
| Weeks | Cohort D: Total | Cohort H2 | Cohort I |
|---|---|---|---|
| Overall Survival for Cohort D, Cohort H2 and Cohort I | 44.29 (1.9 to 228.0) | 103.43 (19.9 to 147.0) | 60.43 (6.6 to 210.6) |
Area under the plasma concentration time-curve. AUC over the dosing interval.
| hr*ng/mL | Cohort A: Treatment 1 | Cohort A: Treatment 2 | Cohort A: Treatment 3 | Cohort A: Treatment 4 | Cohort A: Treatment 5 | Cohort A: Treatment 6 | Cohort B: Treatment 1 | Cohort B: Treatment 2 | Cohort B: Treatment 3 | Cohort B: Treatment 4 | Cohort B: Treatment 5 | Cohort B: Treatment 6 | Cohort B: Treatment 7 | Cohort B: Treatment 8 | Cohort B: Treatment 9 | Cohort B: Treatment 10 | Cohort D: Treatment 1 | Cohort E: Treatment 1 | Cohort E: Treatment 2 | Cohort E: Treatment 3 | Cohort E: Treatment 4 | Cohort E: Treatment 5 | Cohort F: Treatment 1 | Cohort F: Treatment 2 | Cohort F: Treatment 3 | Cohort F: Treatment 4 | Cohort G: Treatment 1 | Cohort G: Treatment 2 | Cohort G: Treatment 3 | Cohort H1 | Cohort H2 | Cohort I | Cohort J1: Treatment 1 | Cohort J1: Treatment 2 | Cohort K: Treatment 1 | Cohort K: Treatment 2 | Cohort K: Treatment 3 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CC-220 | — | 22.5946 ± 3.2396 | 111.1790 ± NA | 66.0413 ± 11.0851 | — | — | 20.1061 ± NA | — | 57.9410 ± NA | — | 119.8230 ± 165.6553 | 45.7555 ± 12.3060 | 96.1991 ± 97.3452 | 84.8140 ± NA | 101.8990 ± NA | 118.5940 ± NA | 181.3199 ± 55.8380 | 14.5430 ± NA | — | — | — | — | 18.3610 ± NA | — | — | — | — | — | — | 196.8304 ± 92.5871 | — | — | — | — | — | — | — |
| CC-17195 | — | — | 5.0220 ± NA | — | — | — | — | — | — | — | 7.2409 ± 67.0218 | — | 11.5310 ± NA | 5.8280 ± NA | 5.7470 ± NA | — | 10.7279 ± 51.1651 | — | — | — | — | — | — | — | — | — | — | — | — | 20.1595 ± 72.6176 | — | — | — | — | — | — | — |
Cmax is defined as maximum plasma concentration of the drug.
| ng/mL | Cohort A: Treatment 1 | Cohort A: Treatment 2 | Cohort A: Treatment 3 | Cohort A: Treatment 4 | Cohort A: Treatment 5 | Cohort A: Treatment 6 | Cohort B: Treatment 1 | Cohort B: Treatment 2 | Cohort B: Treatment 3 | Cohort B: Treatment 4 | Cohort B: Treatment 5 | Cohort B: Treatment 6 | Cohort B: Treatment 7 | Cohort B: Treatment 8 | Cohort B: Treatment 9 | Cohort B: Treatment 10 | Cohort D: Treatment 1 | Cohort E: Treatment 1 | Cohort E: Treatment 2 | Cohort E: Treatment 3 | Cohort E: Treatment 4 | Cohort E: Treatment 5 | Cohort F: Treatment 1 | Cohort F: Treatment 2 | Cohort F: Treatment 3 | Cohort F: Treatment 4 | Cohort G: Treatment 1 | Cohort G: Treatment 2 | Cohort G: Treatment 3 | Cohort H1 | Cohort H2 | Cohort I | Cohort J1: Treatment 1 | Cohort J1: Treatment 2 | Cohort K: Treatment 1 | Cohort K: Treatment 2 | Cohort K: Treatment 3 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CC-220 | 1.5200 ± NA | 1.7944 ± 15.4287 | 10.7000 ± NA | 5.5929 ± 28.1747 | — | — | 1.7600 ± NA | — | 4.7800 ± NA | — | 9.9124 ± 267.2801 | 3.5017 ± 64.5111 | 8.2704 ± 172.8969 | 7.5100 ± NA | 9.9200 ± NA | 7.4627 ± 32.8756 | 12.1183 ± 39.8083 | 2.5200 ± NA | 13.0000 ± NA | 13.9000 ± NA | 6.6900 ± NA | — | 1.3300 ± NA | — | 19.8000 ± NA | — | 5.1600 ± NA | 6.4300 ± NA | — | 15.3411 ± 79.6863 | — | — | — | — | — | — | — |
| CC-17195 | — | — | 0.2980 ± NA | 0.1501 ± 9.9068 | — | — | — | — | 0.2240 ± NA | — | 0.4188 ± 103.5840 | 0.1610 ± NA | 0.3475 ± 104.8825 | 0.3480 ± NA | 0.3550 ± NA | 0.3588 ± 30.8149 | 0.5330 ± 51.5168 | — | 0.3050 ± NA | 0.6700 | — | — | — | — | 0.7240 | — | 0.2430 ± NA | 0.2900 ± NA | — | 0.9957 ± 60.6459 | — | — | — | — | — | — | — |
Tmax is defined is the time to maximum plasma concentration.
| Hours | Cohort A: Treatment 1 | Cohort A: Treatment 2 | Cohort A: Treatment 3 | Cohort A: Treatment 4 | Cohort A: Treatment 5 | Cohort A: Treatment 6 | Cohort B: Treatment 1 | Cohort B: Treatment 2 | Cohort B: Treatment 3 | Cohort B: Treatment 4 | Cohort B: Treatment 5 | Cohort B: Treatment 6 | Cohort B: Treatment 7 | Cohort B: Treatment 8 | Cohort B: Treatment 9 | Cohort B: Treatment 10 | Cohort D: Treatment 1 | Cohort E: Treatment 1 | Cohort E: Treatment 2 | Cohort E: Treatment 3 | Cohort E: Treatment 4 | Cohort E: Treatment 5 | Cohort F: Treatment 1 | Cohort F: Treatment 2 | Cohort F: Treatment 3 | Cohort F: Treatment 4 | Cohort G: Treatment 1 | Cohort G: Treatment 2 | Cohort G: Treatment 3 | Cohort H1 | Cohort H2 | Cohort I | Cohort J1: Treatment 1 | Cohort J1: Treatment 2 | Cohort K: Treatment 1 | Cohort K: Treatment 2 | Cohort K: Treatment 3 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CC-220 | 3.0000 (3.0000 to 3.0000) | 3.5585 (3.000 to 4.117) | 1.0000 (1.0000 to 1.0000) | 1.9415 (1.933 to 1.950) | — | — | 3.0000 (3.0000 to 3.0000) | — | 3.0000 (3.0000 to 3.0000) | — | 2.0085 (1.000 to 3.017) | 2.9580 (1.933 to 3.983) | 2.4915 (2.000 to 2.983) | 2.0170 (2.0170 to 2.0170) | 3.0000 (3.0000 to 3.0000) | 2.9165 (2.833 to 3.000) | 2.0000 (2.0000 to 5.017) | 3.850 (3.850 to 3.850) | 1.000 (1.000 to 1.000) | 2.000 (2.000 to 2.000) | 2.000 (2.000 to 2.000) | — | 5.50 (5.50 to 5.50) | — | 2.00 (2.00 to 2.00) | — | 1.8830 (1.8830 to 1.8830) | 3.6670 (3.6670 to 6.6670) | — | 3.9000 (1.900 to 5.783) | — | — | — | — | — | — | — |
| CC-17195 | — | — | 1.0000 (1.0000 to 1.0000) | 3.4500 (0.967 to 5.933) | — | — | — | — | 2.000 (2.000 to 2.000) | — | 4.9835 (2.050 to 7.917) | 2.9830 (2.9830 to 2.9830) | 3.5085 (3.000 to 4.017) | 1.0170 (1.0170 to 1.0170) | 3.0000 (3.000 to 3.000) | 5.4165 (2.833 to 8.000) | 5.0000 (2.000 to 5.0000) | — | 1.000 (1.000 to 1.000) | 2.000 (2.000 to 2.000) | — | — | — | — | 4.00 (4.00 to 4.00) | — | 7.1000 (7.1000 to 7.1000) | 3.6670 (3.6670 to 3.6670) | — | 6.7415 (1.900 to 8.133) | — | — | — | — | — | — | — |
Collected over Approximately on average of (Cohort A: 16.23 Cohort B: 10.32 Cohort D: 18.68 Cohort E: 15.65 Cohort F: 12.66 Cohort G: 16.03 Cohort H1: 17.22 Cohort H2: 21.07 Cohort I: 17.10 Cohort J: 20.56 Cohort K: 13.56) Months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort A: Treatment 1 | 0/3 (0%) | 2/3 (66.7%) | 3/3 (100%) |
| Cohort A: Treatment 2 | 0/3 (0%) | 1/3 (33.3%) | 3/3 (100%) |
| Cohort A: Treatment 3 | 0/4 (0%) | 2/4 (50%) | 4/4 (100%) |
| Cohort A: Treatment 4 | 1/6 (16.7%) | 3/6 (50%) | 6/6 (100%) |
| Cohort A: Treatment 5 | 0/6 (0%) | 2/6 (33.3%) | 6/6 (100%) |
| Cohort A: Treatment 6 | 0/7 (0%) | 3/7 (42.9%) | 7/7 (100%) |
| Cohort B: Treatment 1 | 1/10 (10%) | 5/10 (50%) | 10/10 (100%) |
| Cohort B: Treatment 2 | 0/3 (0%) | 1/3 (33.3%) | 3/3 (100%) |
| Cohort B: Treatment 3 | 0/3 (0%) | 0/3 (0%) | 3/3 (100%) |
| Cohort B: Treatment 4 | 0/3 (0%) | 2/3 (66.7%) | 3/3 (100%) |
| Cohort B: Treatment 5 | 1/13 (7.7%) | 8/13 (61.5%) | 13/13 (100%) |
| Cohort B: Treatment 6 | 2/13 (15.4%) | 8/13 (61.5%) | 13/13 (100%) |
| Cohort B: Treatment 7 | 0/10 (0%) | 5/10 (50%) | 10/10 (100%) |
| Cohort B: Treatment 8 | 2/8 (25%) | 5/8 (62.5%) | 7/8 (87.5%) |
| Cohort B: Treatment 9 | 2/14 (14.3%) | 9/14 (64.3%) | 13/14 (92.9%) |
| Cohort B: Treatment 10 | 2/13 (15.4%) | 6/13 (46.2%) | 13/13 (100%) |
| Cohort D: Treatment 1 | 82/107 (76.6%) | 61/107 (57%) | 106/107 (99.1%) |
| Cohort E: Treatment 1 | 0/3 (0%) | 1/3 (33.3%) | 3/3 (100%) |
| Cohort E: Treatment 2 | 0/3 (0%) | 2/3 (66.7%) | 3/3 (100%) |
| Cohort E: Treatment 3 | 0/5 (0%) | 3/5 (60%) | 5/5 (100%) |
| Cohort E: Treatment 4 | 1/13 (7.7%) | 5/13 (38.5%) | 13/13 (100%) |
| Cohort E: Treatment 5 | 4/26 (15.4%) | 11/26 (42.3%) | 26/26 (100%) |
| Cohort F: Treatment 1 | 0/3 (0%) | 0/3 (0%) | 3/3 (100%) |
| Cohort F: Treatment 2 | 1/7 (14.3%) | 4/7 (57.1%) | 7/7 (100%) |
| Cohort F: Treatment 3 | 0/10 (0%) | 3/10 (30%) | 10/10 (100%) |
| Cohort F: Treatment 4 | 0/9 (0%) | 6/9 (66.7%) | 8/9 (88.9%) |
| Cohort G: Treatment 1 | 0/4 (0%) | 3/4 (75%) | 4/4 (100%) |
| Cohort G: Treatment 2 | 1/8 (12.5%) | 5/8 (62.5%) | 7/8 (87.5%) |
| Cohort G: Treatment 3 | 1/4 (25%) | 4/4 (100%) | 4/4 (100%) |
| Cohort H1 | 0/6 (0%) | 3/6 (50%) | 6/6 (100%) |
| Cohort H2 | 3/5 (60%) | 1/5 (20%) | 5/5 (100%) |
| Cohort I | 27/41 (65.9%) | 17/41 (41.5%) | 39/41 (95.1%) |
| Cohort J1: Treatment 1 | 0/1 (0%) | 0/1 (0%) | 1/1 (100%) |
| Cohort J1: Treatment 2 | 1/16 (6.3%) | 12/16 (75%) | 16/16 (100%) |
| Cohort J: Doseage Unknown | 0/1 (0%) | 0/1 (0%) | 1/1 (100%) |
| Cohort K: Treatment 1 | 1/25 (4%) | 13/25 (52%) | 24/25 (96%) |
| Cohort K: Treatment 2 | 2/25 (8%) | 11/25 (44%) | 25/25 (100%) |
| Cohort K: Treatment 3 | 2/25 (8%) | 15/25 (60%) | 25/25 (100%) |
| Event | Cohort A: Treatment 1 | Cohort A: Treatment 2 | Cohort A: Treatment 3 | Cohort A: Treatment 4 | Cohort A: Treatment 5 | Cohort A: Treatment 6 | Cohort B: Treatment 1 | Cohort B: Treatment 2 | Cohort B: Treatment 3 | Cohort B: Treatment 4 | Cohort B: Treatment 5 | Cohort B: Treatment 6 | Cohort B: Treatment 7 | Cohort B: Treatment 8 | Cohort B: Treatment 9 | Cohort B: Treatment 10 | Cohort D: Treatment 1 | Cohort E: Treatment 1 | Cohort E: Treatment 2 | Cohort E: Treatment 3 | Cohort E: Treatment 4 | Cohort E: Treatment 5 | Cohort F: Treatment 1 | Cohort F: Treatment 2 | Cohort F: Treatment 3 | Cohort F: Treatment 4 | Cohort G: Treatment 1 | Cohort G: Treatment 2 | Cohort G: Treatment 3 | Cohort H1 | Cohort H2 | Cohort I | Cohort J1: Treatment 1 | Cohort J1: Treatment 2 | Cohort J: Doseage Unknown | Cohort K: Treatment 1 | Cohort K: Treatment 2 | Cohort K: Treatment 3 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BronchitisInfections and infestations | 0/3 | 0/3 | 0/4 | 0/6 | 0/6 | 0/7 | 0/10 | 1/3 | 0/3 | 0/3 | 0/13 | 0/13 | 0/10 | 0/8 | 1/14 | 0/13 | 0/107 | 0/3 | 0/3 | 0/5 | 0/13 | 0/26 | 0/3 | 0/7 | 0/10 | 0/9 | 0/4 | 0/8 | 0/4 | 0/6 | 0/5 | 0/41 | 0/1 | 0/16 | 0/1 | 0/25 | 0/25 | 0/25 |
| CellulitisInfections and infestations | 0/3 | 0/3 | 0/4 | 0/6 | 0/6 | 1/7 | 0/10 | 0/3 | 0/3 | 0/3 | 0/13 | 0/13 | 0/10 | 0/8 | 0/14 | 0/13 | 1/107 | 0/3 | 1/3 | 0/5 | 1/13 | 0/26 | 0/3 | 0/7 | 0/10 | 0/9 | 0/4 | 0/8 | 0/4 | 0/6 | 0/5 | 0/41 | 0/1 | 1/16 | 0/1 | 0/25 | 0/25 | 0/25 |
| ChorioretinitisInfections and infestations | 1/3 | 0/3 | 0/4 | 0/6 | 0/6 | 0/7 | 0/10 | 0/3 | 0/3 | 0/3 | 0/13 | 0/13 | 0/10 | 0/8 | 0/14 | 0/13 | 0/107 | 0/3 | 0/3 | 0/5 | 0/13 | 0/26 | 0/3 | 0/7 | 0/10 | 0/9 | 0/4 | 0/8 | 0/4 | 0/6 | 0/5 | 0/41 | 0/1 | 0/16 | 0/1 | 0/25 | 0/25 | 0/25 |
| Clostridium difficile colitisInfections and infestations | 1/3 | 0/3 | 0/4 | 0/6 | 0/6 | 0/7 | 0/10 | 0/3 | 0/3 | 0/3 | 0/13 | 0/13 | 0/10 | 0/8 | 0/14 | 0/13 | 0/107 | 0/3 | 0/3 | 0/5 | 0/13 | 0/26 | 0/3 | 0/7 | 0/10 | 0/9 | 0/4 | 0/8 | 0/4 | 0/6 | 0/5 | 0/41 | 0/1 | 0/16 | 0/1 | 0/25 | 0/25 | 0/25 |
| Cytomegalovirus chorioretinitisInfections and infestations | 1/3 | 0/3 | 0/4 | 0/6 | 0/6 | 0/7 | 0/10 | 0/3 | 0/3 | 0/3 | 0/13 | 0/13 | 0/10 | 0/8 | 0/14 | 0/13 | 0/107 | 0/3 | 0/3 | 0/5 | 0/13 | 1/26 | 0/3 | 0/7 | 0/10 | 0/9 | 0/4 | 0/8 | 0/4 | 0/6 | 0/5 | 0/41 | 0/1 | 0/16 | 0/1 | 0/25 | 1/25 | 0/25 |
| Device related infectionInfections and infestations | 0/3 | 0/3 | 0/4 | 0/6 | 0/6 | 0/7 | 0/10 | 1/3 | 0/3 | 0/3 | 0/13 | 0/13 | 0/10 | 0/8 | 0/14 | 0/13 | 0/107 | 0/3 | 0/3 | 0/5 | 0/13 | 0/26 | 0/3 | 0/7 | 0/10 | 0/9 | 0/4 | 0/8 | 0/4 | 0/6 | 0/5 | 0/41 | 0/1 | 0/16 | 0/1 | 0/25 | 0/25 | 0/25 |
| Gastroenteritis rotavirusInfections and infestations | 0/3 | 0/3 | 0/4 | 0/6 | 0/6 | 0/7 | 0/10 | 0/3 | 0/3 | 1/3 | 0/13 | 0/13 | 0/10 | 0/8 | 0/14 | 0/13 | 0/107 | 0/3 | 0/3 | 0/5 | 0/13 | 0/26 | 0/3 | 0/7 | 0/10 | 0/9 | 0/4 | 0/8 | 0/4 | 0/6 | 0/5 | 0/41 | 0/1 | 0/16 | 0/1 | 0/25 | 0/25 | 0/25 |
| Lower respiratory tract infectionInfections and infestations | 0/3 | 1/3 | 0/4 | 1/6 | 1/6 | 0/7 | 1/10 | 0/3 | 0/3 | 0/3 | 0/13 | 0/13 | 0/10 | 1/8 | 0/14 | 0/13 | 0/107 | 0/3 | 0/3 | 1/5 | 0/13 | 0/26 | 0/3 | 0/7 | 0/10 | 0/9 | 0/4 | 0/8 | 0/4 | 0/6 | 0/5 | 0/41 | 0/1 | 0/16 | 0/1 | 0/25 | 0/25 | 0/25 |
| Lower respiratory tract infection viralInfections and infestations | 0/3 | 0/3 | 0/4 | 0/6 | 0/6 | 0/7 | 0/10 | 0/3 | 0/3 | 1/3 | 0/13 | 0/13 | 0/10 | 0/8 | 0/14 | 0/13 | 0/107 | 0/3 | 0/3 | 0/5 | 0/13 | 0/26 | 0/3 | 0/7 | 0/10 | 0/9 | 0/4 | 0/8 | 0/4 | 0/6 | 0/5 | 0/41 | 0/1 | 0/16 | 0/1 | 0/25 | 0/25 | 0/25 |
| Pneumocystis jirovecii pneumoniaInfections and infestations | 0/3 | 0/3 | 0/4 | 0/6 | 0/6 | 0/7 | 0/10 | 0/3 | 0/3 | 0/3 | 0/13 | 0/13 | 0/10 | 0/8 | 1/14 | 0/13 | 0/107 | 0/3 | 1/3 | 0/5 | 0/13 | 0/26 | 0/3 | 0/7 | 0/10 | 0/9 | 0/4 | 0/8 | 0/4 | 0/6 | 0/5 | 1/41 | 0/1 | 0/16 | 0/1 | 0/25 | 0/25 | 0/25 |
| Event | Cohort A: Treatment 1 | Cohort A: Treatment 2 | Cohort A: Treatment 3 | Cohort A: Treatment 4 | Cohort A: Treatment 5 | Cohort A: Treatment 6 | Cohort B: Treatment 1 | Cohort B: Treatment 2 | Cohort B: Treatment 3 | Cohort B: Treatment 4 | Cohort B: Treatment 5 | Cohort B: Treatment 6 | Cohort B: Treatment 7 | Cohort B: Treatment 8 | Cohort B: Treatment 9 | Cohort B: Treatment 10 | Cohort D: Treatment 1 | Cohort E: Treatment 1 | Cohort E: Treatment 2 | Cohort E: Treatment 3 | Cohort E: Treatment 4 | Cohort E: Treatment 5 | Cohort F: Treatment 1 | Cohort F: Treatment 2 | Cohort F: Treatment 3 | Cohort F: Treatment 4 | Cohort G: Treatment 1 | Cohort G: Treatment 2 | Cohort G: Treatment 3 | Cohort H1 | Cohort H2 | Cohort I | Cohort J1: Treatment 1 | Cohort J1: Treatment 2 | Cohort J: Doseage Unknown | Cohort K: Treatment 1 | Cohort K: Treatment 2 | Cohort K: Treatment 3 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 2/3 | 1/3 | 3/4 | 2/6 | 2/6 | 3/7 | 4/10 | 1/3 | 0/3 | 0/3 | 7/13 | 4/13 | 6/10 | 4/8 | 6/14 | 3/13 | 44/107 | 1/3 | 2/3 | 2/5 | 3/13 | 9/26 | 0/3 | 2/7 | 5/10 | 2/9 | 1/4 | 3/8 | 1/4 | 2/6 | 2/5 | 14/41 | 0/1 | 6/16 | 1/1 | 7/25 | 12/25 | 5/25 |
| LeukopeniaBlood and lymphatic system disorders | 0/3 | 0/3 | 0/4 | 0/6 | 2/6 | 1/7 | 1/10 | 0/3 | 1/3 | 0/3 | 0/13 | 1/13 | 3/10 | 4/8 | 1/14 | 4/13 | 30/107 | 1/3 | 1/3 | 1/5 | 6/13 | 12/26 | 0/3 | 1/7 | 0/10 | 1/9 | 2/4 | 2/8 | 1/4 | 3/6 | 0/5 | 14/41 | 1/1 | 1/16 | 0/1 | 4/25 | 7/25 | 6/25 |
| LymphopeniaBlood and lymphatic system disorders | 0/3 | 0/3 | 0/4 | 0/6 | 0/6 | 1/7 | 0/10 | 0/3 | 0/3 | 0/3 | 1/13 | 1/13 | 1/10 | 2/8 | 1/14 | 3/13 | 20/107 | 2/3 | 1/3 | 0/5 | 4/13 | 6/26 | 1/3 | 1/7 | 0/10 | 0/9 | 3/4 | 3/8 | 1/4 | 2/6 | 1/5 | 9/41 | 1/1 | 4/16 | 1/1 | 7/25 | 10/25 | 7/25 |
| NeutropeniaBlood and lymphatic system disorders | 1/3 | 2/3 | 2/4 | 4/6 | 4/6 | 3/7 | 3/10 | 3/3 | 0/3 | 1/3 | 6/13 | 4/13 | 4/10 | 4/8 | 9/14 | 9/13 | 66/107 | 1/3 | 2/3 | 4/5 | 10/13 | 23/26 | 2/3 | 3/7 | 4/10 | 5/9 | 2/4 | 3/8 | 2/4 | 6/6 | 5/5 | 24/41 | 1/1 | 6/16 | 0/1 | 18/25 | 22/25 | 20/25 |
| ThrombocytopeniaBlood and lymphatic system disorders | 1/3 | 1/3 | 2/4 | 2/6 | 1/6 | 1/7 | 1/10 | 0/3 | 0/3 | 0/3 | 4/13 | 0/13 | 4/10 | 2/8 | 1/14 | 5/13 | 40/107 | 1/3 | 2/3 | 2/5 | 4/13 | 8/26 | 0/3 | 3/7 | 3/10 | 3/9 | 1/4 | 4/8 | 2/4 | 2/6 | 4/5 | 12/41 | 1/1 | 5/16 | 0/1 | 5/25 | 5/25 | 6/25 |
| ChalazionEye disorders | 0/3 | 0/3 | 0/4 | 0/6 | 0/6 | 0/7 | 0/10 | 0/3 | 0/3 | 0/3 | 0/13 | 0/13 | 0/10 | 0/8 | 0/14 | 0/13 | 0/107 | 0/3 | 0/3 | 0/5 | 1/13 | 0/26 | 1/3 | 0/7 | 0/10 | 0/9 | 0/4 | 0/8 | 0/4 | 0/6 | 0/5 | 0/41 | 1/1 | 0/16 | 0/1 | 0/25 | 0/25 | 0/25 |
| ConstipationGastrointestinal disorders | 1/3 | 1/3 | 2/4 | 2/6 | 1/6 | 1/7 | 1/10 | 0/3 | 0/3 | 0/3 | 0/13 | 2/13 | 3/10 | 4/8 | 1/14 | 2/13 | 25/107 | 0/3 | 1/3 | 3/5 | 2/13 | 3/26 | 1/3 | 3/7 | 1/10 | 2/9 | 0/4 | 0/8 | 0/4 | 2/6 | 2/5 | 11/41 | 1/1 | 9/16 | 1/1 | 11/25 | 7/25 | 8/25 |
| DyspepsiaGastrointestinal disorders | 0/3 | 1/3 | 1/4 | 0/6 | 0/6 | 0/7 | 0/10 | 0/3 | 0/3 | 0/3 | 0/13 | 1/13 | 0/10 | 0/8 | 2/14 | 0/13 | 3/107 | 0/3 | 1/3 | 0/5 | 0/13 | 0/26 | 0/3 | 0/7 | 2/10 | 0/9 | 0/4 | 0/8 | 0/4 | 0/6 | 0/5 | 4/41 | 1/1 | 2/16 | 1/1 | 0/25 | 1/25 | 1/25 |
| AstheniaGeneral disorders | 0/3 | 0/3 | 0/4 | 0/6 | 0/6 | 1/7 | 0/10 | 2/3 | 0/3 | 0/3 | 1/13 | 0/13 | 1/10 | 2/8 | 1/14 | 1/13 | 18/107 | 0/3 | 0/3 | 1/5 | 0/13 | 2/26 | 0/3 | 2/7 | 2/10 | 1/9 | 0/4 | 0/8 | 0/4 | 0/6 | 0/5 | 1/41 | 0/1 | 4/16 | 1/1 | 5/25 | 7/25 | 5/25 |
| FatigueGeneral disorders | 3/3 | 2/3 | 2/4 | 3/6 | 3/6 | 3/7 | 4/10 | 1/3 | 0/3 | 2/3 | 3/13 | 4/13 | 5/10 | 4/8 | 5/14 | 6/13 | 26/107 | 0/3 | 2/3 | 2/5 | 6/13 | 9/26 | 0/3 | 3/7 | 4/10 | 4/9 | 2/4 | 4/8 | 2/4 | 0/6 | 0/5 | 16/41 | 1/1 | 6/16 | 0/1 | 7/25 | 8/25 | 5/25 |
| Age, Customized(Participants) | Cohort A: Treatment 1 | Cohort A: Treatment 2 | Cohort A: Treatment 3 | Cohort A: Treatment 4 | Cohort A: Treatment 5 | Cohort A: Treatment 6 | Cohort B: Treatment 1 | Cohort B: Treatment 2 | Cohort B: Treatment 3 | Cohort B: Treatment 4 | Cohort B: Treatment 5 | Cohort B: Treatment 6 | Cohort B: Treatment 7 | Cohort B: Treatment 8 | Cohort B: Treatment 9 | Cohort B: Treatment 10 | Cohort D: Treatment 1 | Cohort E: Treatment 1 | Cohort E: Treatment 2 | Cohort E: Treatment 3 | Cohort E: Treatment 4 | Cohort E: Treatment 5 | Cohort F: Treatment 1 | Cohort F: Treatment 2 | Cohort F: Treatment 3 | Cohort F: Treatment 4 | Cohort G: Treatment 1 | Cohort G: Treatment 2 | Cohort G: Treatment 3 | Cohort H1 | Cohort H2 | Cohort I | Cohort J1: Treatment 1 | Cohort J1: Treatment 2 | Cohort K: Treatment 1 | Cohort K: Treatment 2 | Cohort K: Treatment 3 | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 18 - 64 years old | 2 | 2 | 3 | 2 | 1 | 3 | 5 | 1 | 2 | 2 | 7 | 5 | 5 | 2 | 6 | 6 | 54 | 2 | 2 | 0 | 7 | 12 | 2 | 5 | 4 | 5 | 2 | 5 | 1 | 2 | 0 | 19 | 0 | 1 | 0 | 2 | 2 | 181 |
| 65 - 84 years old | 1 | 1 | 1 | 4 | 5 | 4 | 5 | 2 | 1 | 1 | 6 | 8 | 5 | 6 | 8 | 7 | 53 | 1 | 1 | 5 | 6 | 14 | 1 | 2 | 6 | 4 | 2 | 3 | 3 | 4 | 4 | 22 | 1 | 16 | 25 | 22 | 22 | 282 |
| 85+ years old | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 1 | 3 |
| Sex: Female, Male(Participants) | Cohort A: Treatment 1 | Cohort A: Treatment 2 | Cohort A: Treatment 3 | Cohort A: Treatment 4 | Cohort A: Treatment 5 | Cohort A: Treatment 6 | Cohort B: Treatment 1 | Cohort B: Treatment 2 | Cohort B: Treatment 3 | Cohort B: Treatment 4 | Cohort B: Treatment 5 | Cohort B: Treatment 6 | Cohort B: Treatment 7 | Cohort B: Treatment 8 | Cohort B: Treatment 9 | Cohort B: Treatment 10 | Cohort D: Treatment 1 | Cohort E: Treatment 1 | Cohort E: Treatment 2 | Cohort E: Treatment 3 | Cohort E: Treatment 4 | Cohort E: Treatment 5 | Cohort F: Treatment 1 | Cohort F: Treatment 2 | Cohort F: Treatment 3 | Cohort F: Treatment 4 | Cohort G: Treatment 1 | Cohort G: Treatment 2 | Cohort G: Treatment 3 | Cohort H1 | Cohort H2 | Cohort I | Cohort J1: Treatment 1 | Cohort J1: Treatment 2 | Cohort K: Treatment 1 | Cohort K: Treatment 2 | Cohort K: Treatment 3 | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | 1 | 2 | 1 | 3 | 3 | 4 | 5 | 1 | 0 | 0 | 8 | 7 | 5 | 4 | 9 | 8 | 47 | 0 | 2 | 2 | 6 | 17 | 1 | 1 | 2 | 6 | 1 | 3 | 3 | 4 | 3 | 21 | 1 | 5 | 12 | 12 | 9 | 219 |
| Male | 2 | 1 | 3 | 3 | 3 | 3 | 5 | 2 | 3 | 3 | 5 | 6 | 5 | 4 | 5 | 5 | 60 | 3 | 1 | 3 | 7 | 9 | 2 | 6 | 8 | 3 | 3 | 5 | 1 | 2 | 2 | 20 | 0 | 12 | 13 | 13 | 16 | 247 |
| Ethnicity (NIH/OMB)(Participants) | Cohort A: Treatment 1 | Cohort A: Treatment 2 | Cohort A: Treatment 3 | Cohort A: Treatment 4 | Cohort A: Treatment 5 | Cohort A: Treatment 6 | Cohort B: Treatment 1 | Cohort B: Treatment 2 | Cohort B: Treatment 3 | Cohort B: Treatment 4 | Cohort B: Treatment 5 | Cohort B: Treatment 6 | Cohort B: Treatment 7 | Cohort B: Treatment 8 | Cohort B: Treatment 9 | Cohort B: Treatment 10 | Cohort D: Treatment 1 | Cohort E: Treatment 1 | Cohort E: Treatment 2 | Cohort E: Treatment 3 | Cohort E: Treatment 4 | Cohort E: Treatment 5 | Cohort F: Treatment 1 | Cohort F: Treatment 2 | Cohort F: Treatment 3 | Cohort F: Treatment 4 | Cohort G: Treatment 1 | Cohort G: Treatment 2 | Cohort G: Treatment 3 | Cohort H1 | Cohort H2 | Cohort I | Cohort J1: Treatment 1 | Cohort J1: Treatment 2 | Cohort K: Treatment 1 | Cohort K: Treatment 2 | Cohort K: Treatment 3 | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 3 | 0 | 1 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 2 | 1 | 1 | 0 | 0 | 1 | 0 | 1 | 1 | 2 | 0 | 18 |
| Not Hispanic or Latino | 3 | 2 | 4 | 4 | 4 | 7 | 6 | 3 | 2 | 2 | 13 | 11 | 10 | 6 | 14 | 13 | 97 | 3 | 1 | 5 | 12 | 25 | 2 | 7 | 9 | 9 | 1 | 7 | 3 | 6 | 5 | 40 | 1 | 15 | 24 | 21 | 23 | 420 |
| Unknown or Not Reported | 0 | 0 | 0 | 2 | 2 | 0 | 3 | 0 | 1 | 1 | 0 | 1 | 0 | 2 | 0 | 0 | 7 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 2 | 2 | 28 |
| Race (NIH/OMB)(Participants) | Cohort A: Treatment 1 | Cohort A: Treatment 2 | Cohort A: Treatment 3 | Cohort A: Treatment 4 | Cohort A: Treatment 5 | Cohort A: Treatment 6 | Cohort B: Treatment 1 | Cohort B: Treatment 2 | Cohort B: Treatment 3 | Cohort B: Treatment 4 | Cohort B: Treatment 5 | Cohort B: Treatment 6 | Cohort B: Treatment 7 | Cohort B: Treatment 8 | Cohort B: Treatment 9 | Cohort B: Treatment 10 | Cohort D: Treatment 1 | Cohort E: Treatment 1 | Cohort E: Treatment 2 | Cohort E: Treatment 3 | Cohort E: Treatment 4 | Cohort E: Treatment 5 | Cohort F: Treatment 1 | Cohort F: Treatment 2 | Cohort F: Treatment 3 | Cohort F: Treatment 4 | Cohort G: Treatment 1 | Cohort G: Treatment 2 | Cohort G: Treatment 3 | Cohort H1 | Cohort H2 | Cohort I | Cohort J1: Treatment 1 | Cohort J1: Treatment 2 | Cohort K: Treatment 1 | Cohort K: Treatment 2 | Cohort K: Treatment 3 | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 6 | 5 | 0 | 0 | 0 | 5 | 4 | 2 | 23 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 1 | 0 | 0 | 0 | 1 | 1 | 2 | 0 | 1 | 0 | 2 | 2 | 1 | 0 | 2 | 2 | 15 | 2 | 1 | 1 | 0 | 5 | 0 | 2 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 5 | 0 | 0 | 2 | 1 | 1 | 51 |
| White | 2 | 3 | 4 | 4 | 3 | 6 | 6 | 3 | 1 | 2 | 10 | 10 | 9 | 6 | 12 | 11 | 84 | 1 | 1 | 4 | 12 | 20 | 3 | 4 | 8 | 8 | 3 | 8 | 4 | 0 | 0 | 34 | 1 | 16 | 16 | 18 | 19 | 356 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 2 | 2 | 0 | 2 | 0 | 1 | 1 | 1 | 1 | 0 | 2 | 0 | 0 | 8 | 0 | 1 | 0 | 1 | 1 | 0 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 2 | 0 | 1 | 2 | 2 | 3 | 36 |
Showing the first 100 of 162 sites across 11 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: See Plan Description
Access criteria: See Plan Description
Data sharing details ↗ · www.bms.com
Ran from Oct 2016 to primary completion in May 2024, 90 months.
Results were first posted in Mar 2026, 1 year 10 months after primary completion.
Of 98 industry-sponsored phase 1/2 interventional studies under Multiple Myeloma, half reached primary completion within 64 months of starting (the median), counting those still running; a quarter within 42 and three quarters within 90. This study's 90 months is above that.
Counting every sponsor, half of 201 studies reached it within 65 months; a quarter within 44 and three quarters within 92.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Iberdomide · Daratumumab